Industry context
BioNTech SE [BNTX]
Dernière mise à jour 25 Jun 2026 @ 16:00 (Exchange is closed)
Dernier : $90.00
-0.23%
-2.45
GaG Algo Score™
v1.0
Court
-2.45
Moyen
-3.97
Long
-3.61
ACHAT
58.00%
rendement -8.08%
VENTE
59.18%
rendement -8.63%
Ligne
Données pivot
Statistiques pivot
| Métrique | Moyenne | Médiane | Écart type |
|---|---|---|---|
| Gain % | 8.58% | 8.58% | 1.01% |
| Perte % | -10.89% | -10.89% | 0.00% |
| Durée | 9.7d | 10d | 0.6d |
| Total des pivots trouvés | 4 |
| Segments gain/perte | 3 (2 Gain / 1 Perte) |
| Dernier pivot | Top @ $92.22 le 2026-06-17 |
| Variation depuis le dernier pivot | $-2.22 (-2.41%) |
Prévision du prochain pivot Dernier : $90.00
| Prochain type prévu | Bottom |
| Prix prévu (moy.) | $82.18 |
| Prix prévu (médiane) | $82.18 |
| Fourchette de prix prévue (~68%) | $82.18 - $82.18 |
| Variation vers cible moyenne | $-7.82 (-8.69%) |
| Date prévue (moy.) | 2026-06-26 |
| Plage de dates prévue (~68%) | 2026-06-26 - 2026-06-27 |
| Base | Based on 1 historical losses (Avg: -10.89%, Median: -10.89%, StdDev of Abs: 0.00%) and duration (Avg: 9.7 days, StdDev: 0.6 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Slight loss for BioNTech SE.
BioNTech SE (BNTX) stock price inched lower on Thursday after the stock fell $-0.210 (-0.23%) from the previous session on below-average volume. The stock moved in line with the falling NASDAQ that fell -0.46%. With 701 955 shares traded, volume yesterday reached $63.18M. This was 738 745 shares less than the prior day. Compared to the 10-day average of 1.18M shares, volume was less than the average.
BioNTech SE signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-33.3%), medium- (-33.3%), and long-term (-33.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
BioNTech SE Support & Resistance Levels
The stock is trading above the closest support level at $89.00. approximately $1.000 (1.11%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s189 -
BioNTech SE Evaluation
- Court score: -2.45
- Moyen score: -3.97
- Long score: -3.61
Ownership flow
GetAGraph InsiderPower
Transactions
49
Buy power
22.63M
Sell power
11.06M
Reliability
100/100
Buy / sell
2.05
Hist. corr.
0.45
Latest signal
Sell 2026-05-07
Officer 60
Director 8
Other 1
2029-05-28
Sahin Ugur Officer
Other 18 747
2029-05-28
Ryan James Timothy Patrick Officer
Other 8 838
2029-05-28
Sahin Ugur Officer
Other 18 747
2029-05-28
Ryan James Timothy Patrick Officer
Other 8 838
2029-05-28
Poetting Sierk Officer
Other 8 838
2029-05-28
Tureci Ozlem Officer
Other 9 306
Relationship map
Correlation snapshot
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.29% <strong>$90.23</strong> paired level.</span>
Least
IALT -0.83Positioning pressure
Short interest pressure
Short interest
0.94%
Of outstanding shares
Short float
0.94%
Of tradable float
Days to cover
2.38
Short interest divided by average volume
Squeeze probability
1.40%
-8.03% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2026-05-29Income profile
Dividend profile
Dernier dividende
$2.11
2022-06-02
Prochain dividende
$0
N/A
Avg. yearly yield
0.06%
Insufficient data to determine frequency
Total paid
$2.11
1 payments
Sustainability
0
low (50.00%)
Growth potential
0
No dividend growth expected in the near future
Direction
0
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $2.11 | 0.91% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2022-06-02 | $2.11 | 2022-06-17 |
Earnings quality
Earnings history
Reported quarters
11
EPS beats
7
EPS misses
4
Avg. surprise
208.89%
BioNTech SE Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Beat
Q1/2023
Miss
Q2/2023
Beat
Q3/2023
Miss
Q4/2023
Miss
Q1/2024
Miss
Q2/2024
Beat
Q3/2024
Beat
Q4/2024
Beat
Q1/2025
Waiting
Q2/2025
BioNTech SE Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-08-04 | Q2/2025 | $-2.67 | - | Waiting | 155.26M | - | Waiting |
| 2025-05-05 | Q1/2025 | $-2.77 | $-1.959 | Beat 29.27% | 148.86M | 197.76M | Beat 32.85% |
| 2025-03-10 | Q4/2024 | $0.610 | $1.150 | Beat 88.52% | 173.65M | 1.23B | Beat 609.60% |
| 2024-11-04 | Q3/2024 | $-1.560 | $0.810 | Beat 151.92% | 1.32B | 1.24B | Miss -6.05% |
| 2024-08-05 | Q2/2024 | $-2.16 | $-3.62 | Miss -67.59% | 171.37M | 128.70M | Miss -24.90% |
| 2024-05-06 | Q1/2024 | $-0.820 | $-1.420 | Miss -73.17% | 170.40M | 187.60M | Beat 10.09% |
| 2024-03-20 | Q4/2023 | $2.42 | $1.900 | Miss -21.49% | 1.99B | 1.48B | Miss -25.55% |
| 2023-11-06 | Q3/2023 | $-0.100 | $0.670 | Beat 770.00% | 2.33B | 895.30M | Miss -61.55% |
| 2023-08-07 | Q2/2023 | $-0.750 | $-0.860 | Miss -14.67% | 740.46M | 167.70M | Miss -77.35% |
| 2023-05-08 | Q1/2023 | $0.140 | $2.05 | Beat 1 364.29% | 1.59B | 1.28B | Miss -19.62% |
| 2023-03-27 | Q4/2022 | $7.99 | $9.26 | Beat 15.89% | 4.25B | 4.28B | Beat 0.72% |
| 2022-11-07 | Q3/2022 | $4.51 | $6.98 | Beat 54.77% | 2.02B | 3.46B | Beat 71.03% |
Analyst view
Analyst targets
Consensus
$132.33
Median
$135.00
Low
$96.00
High
$158.00
News flow
Latest company news
Market coverage
reuters.com Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO Jun 17, 2026 zacks.com Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study Jun 4, 2026 zacks.com Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO Jun 1, 2026 globenewswire.com Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial May 30, 2026Company releases
Company context
Company profile
Bourse :
NASDAQ
Secteur :
Healthcare
Industrie :
Biotechnology
Currency
USD
BioNTech SE a biotechnology firm specializes in the creation and marketing of immunebased treatments for malignancies and various infectious diseases A significant part of its oncology pipeline includes the FixVac cancer vaccine program which features several candidates in different phases of clinical development BNT111 is in Phase 2 for advanced melanoma BNT112 has reached Phase 12a for prostate cancer BNT113 is undergoing Phase 2 investigation for HPVpositive head and neck cancers BNT114 is in Phase 1 for triplenegative breast cancer BNT115 is also in Phase 1 targeting ovarian cancer BNT116 is a preclinical candidate for nonsmall cell lung cancer The company also pioneers personalized therapies that target neoantigens such as Autogene cevumeran BNT122 which is in Phase 2 for firstline melanoma and Phase 1a1b for a range of solid tumors Furthermore its pipeline includes an mRNAbased intratumoral immunotherapy SAR441000 currently in Phase 1 for solid tumors as well as BNT141 and BNT142 also in Phase 1 for multiple solid tumors BioNTechs portfolio extends to RiboCytokine therapies BNT151 BNT152 and BNT153 aimed at solid tumors and cuttingedge chimeric antigen receptor Tcell CAR Tcell immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer Immune checkpoint modulators specifically GEN1046 and GEN1042 are also under Phase 12 clinical investigation for solid tumors Beyond these the firm is developing BNT321 an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer and BNT411 a small molecule immunomodulator candidate for solid tumors Its broader scope encompasses preventative vaccines for illnesses like COVID19 and Influenza additional immunotherapies for infectious diseases and protein replacement therapies designed for rare conditions To advance its extensive pipeline BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms including Genentech Sanofi SA Genmab AS Pfizer Inc Shanghai Fosun Pharmaceutical Group Co Ltd and Regeneron Pharmaceuticals Inc Established in 2008 BioNTech SE maintains its principal operations in Mainz Germany
Navigation